Document is current
Any future updates will be listed below
-
Authors
Muñoz-Castro, Clara https://orcid.org/0000-0002-4484-9802
Healey, Molly A. https://orcid.org/0009-0008-6279-1094
Noori, Ayush https://orcid.org/0000-0003-1420-1236
Jaisa-aad, Methasit https://orcid.org/0000-0003-2994-2416
Gómez-Méndez, Paula
Jayakumar, Rojashree https://orcid.org/0009-0008-1693-3063
Alla, Srinija
Kashlan, Zane D. https://orcid.org/0000-0001-7605-330X
Fan, Zhanyun
Zaniewski, Eric F. https://orcid.org/0009-0007-9309-5481
Animesh, Sambhavi https://orcid.org/0000-0003-0692-4434
Morris, Robert T.
Calvo-Rodriguez, Maria https://orcid.org/0000-0001-6947-5547
Hudry, Eloise https://orcid.org/0000-0003-3654-9663
Das, Sudeshna https://orcid.org/0000-0002-9486-6811
Haas, Wilhelm
Hyman, Bradley T. https://orcid.org/0000-0002-7959-9401
Serrano-Pozo, Alberto https://orcid.org/0000-0003-0899-7530
- License Information
-
More Information
Article History
Received: 30 November 2025
Accepted: 17 August 2026
First Online: 25 August 2026
Declarations
Ethics approval and consent to participate: The brain donors or their next-of-kin provided written informed consent for the brain donation, which was performed under a protocol approved by the Massachusetts General Hospital Institutional Review Board (protocol #1999P009556) in accordance with the ethical principles set forth in the Declaration of Helsinki. All mouse experiments were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (protocol #2019N000107).
Competing interests: MC-R is currently an employee at AbbVie, Inc. EH is an employee at Novartis Institutes for BioMedical Research. BTH has a family member who works at Novartis and owns stock in Novartis; serves on the scientific advisory board of Dewpoint and owns stock; serves on a scientific advisory board or is a consultant for AbbVie, Arvinas, Biogen, Novartis, Cell Signaling Technologies, Sangamo, Sanofi, Takeda, US Department of Justice, and Vigil; and his laboratory is supported by sponsored research agreements with Abbvie, F Prime, and Spark. AS-P has a material transfer agreement with Ionis Pharmaceuticals, Inc. and has received research funds from AbbVie, Inc.
